The Company conducts its continuing operations through the Fabrication Technology and Medical Technology operating segments, which also represent the Company’s reportable segments.

▪Fabrication Technology - a global supplier of consumable products and equipment for cutting, joining, and automated welding, as well as gas control equipment, providing a wide range of products with innovative technologies to solve challenges in virtually any industry.

•Medical Technology - a global leader in orthopedic solutions, providing orthopedic devices, reconstructive implants, software and services spanning the full continuum of patient care, from injury prevention to rehabilitation.

Certain amounts not allocated to the two reportable segments and intersegment eliminations are reported under the heading “Corporate and other.” The Company’s management evaluates the operating results of each of its reportable segments based upon Net sales and segment operating income (loss), which represents Operating income (loss) before Restructuring and other related charges and European Union Medical Devices Regulation (“MDR”) and other costs.


	Three Months Ended				Nine Months Ended
	October 2, 2020		September 27, 2019		October 2, 2020		September 27, 2019(1)
	(In thousands)
Net sales:
Fabrication Technology	$	491,497	$	539,228	$	1,431,401	$	1,692,347
Medical Technology	314,434		307,291		811,246		746,738
	$	805,931	$	846,519	$	2,242,647	$	2,439,085
Segment operating income (loss)(2):
Fabrication Technology	$	63,058	$	72,999	$	175,703	$	224,574
Medical Technology	22,869		22,456		5,877		37,743
Corporate and other	(15,079)		(14,285)		(44,730)		(99,864)
	$	70,848	$	81,170	$	136,850	$	162,453

(1) For the nine months ended September 27, 2019, the Medical Technology segment includes results from the acquisition date of February 22, 2019.

(2) Following is a reconciliation of Income (loss) from continuing operations before income taxes to segment operating income:


	Three Months Ended				Nine Months Ended
	October 2, 2020		September 27, 2019		October 2, 2020		September 27, 2019
	(In thousands)
Income (loss) from continuing operations before income taxes	$	36,364	$	2,417	$	25,200	$	(8,708)

Pension settlement loss	—		33,616		—		33,616
Interest expense, net	25,567		31,828		78,647		86,820
Restructuring and other related charges(1)	6,328		13,309		28,514		50,725
MDR and other(2)	2,589		—		4,489		—
Segment operating income	$	70,848	$	81,170	$	136,850	$	162,453

(1) Restructuring and other related charges includes $2.2 million and $4.9 million of expense classified as Cost of sales on the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended October 2, 2020, respectively, and $3.5 million of expense classified as Cost of sales on the Company’s Condensed Consolidated Statements of Operations for the three and nine months ended September 27, 2019.

(2) Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union Medical Device Regulation of 2017.